Diagnosis | Months to HCT | Proportion of patients with ≤ 6, > 6 and < 12, and ≥ 12 months between their initial diagnosis and HCT | |||
---|---|---|---|---|---|
Mean (SD) | Median | ≤6 months | > 6 and < 12 months | ≥12 months | |
All patients (N = 2663) | 12.5 (15.7) | 6.3 | 1287 (48.3%) | 573 (21.5%) | 807 (30.2%) |
Acute lymphocytic leukemia (N = 346) | 8.1 (10.0) | 4.9 | 210 (60.7%) | 82 (23.7%) | 54 (15.6%) |
Acute myelogenous leukemia (N = 984) | 8.1 (10.5) | 4.4 | 650 (66.1%) | 156 (15.9%) | 178 (18.0%) |
Non-Hodgkin’s lymphoma (N = 447) | 21.0 (20.8) | 13.7 | 97 (21.7%) | 105 (23.5%) | 245 (54.8%) |
Myelodysplastic syndrome (N = 330) | 12.4 (17.4) | 6.4 | 154 (46.7%) | 90 (27.3%) | 86 (26.0%) |
Myeloproliferative disorders (N = 148) | 14.5 (18.6) | 7.8 | 61 (41.2%) | 36 (24.3%) | 51 (34.5%) |